Sep 2026· Signal Transduction and Targeted Therapy· Vol 11· 0 citations· 50 references
Medicine
TL;DR
A conserved IFNAR1-driven circuit mediated by iron homeostasis that sustains neutrophil pathogenicity across distinct mucosal tissues is defined and a targetable metabolic node for selectively disarming pathogenic neutrophil responses in the setting of chronic inflammatory disease is identified.
Abstract
Neutrophils are double-edged effectors of the innate immune system: while essential for host defense, they can drive significant tissue damage in the context of chronic inflammatory diseases. Identifying strategies to selectively dampen their pathogenic functions without compromising antimicrobial immunity remains a major clinical challenge. Here, we define a conserved IFNAR1-driven circuit mediated by iron homeostasis that sustains neutrophil pathogenicity across distinct mucosal tissues. Using single-cell transcriptomics and a CRISPR-based functional screen, we identified the mitochondrial iron transporter Mitoferrin-1 (SLC25A37) as a key regulator of neutrophil inflammatory programming. Mechanistically, our data indicate that Mitoferrin-1 mediates a feedforward loop in which NET-derived histones activate toll-like receptor 9 (TLR9), which in turn sustains IFN-α/IFNAR1 signaling, rewires mitochondrial metabolism, and ultimately drives tissue damage through markedly increased of NETosis, reactive oxygen species production, and degranulation. Notably, this IFNAR1-driven inflammatory circuit operates entirely independently of antimicrobial function, as pharmacological IFNAR1 blockade fully preserves phagocytic activity against bacterial pathogens in vivo. Targeting this pathway selectively attenuates neutrophil-driven inflammation in both murine models of colitis and acute lung injury, as well as in primary human intestinal organoid systems. Together, these findings identify a targetable metabolic node for selectively disarming pathogenic neutrophil responses in the setting of chronic inflammatory disease.
This review delineates how bacterial pathogens both induce excessive NET formation, driving endothelial dysfunction, and evade NET-mediated antimicrobial defense and critically examines the signaling crosstalk between the NET formation with other cell death pathways, particularly focusing on the ROS-mediated PAD4-RIPK...
Shwetha Susan Thomas, Geetha B. Kumar, Bipin G. Nair et al.· Frontiers in Immunology· 0 citations
It is shown that chronic inflammatory signaling can ultimately trigger a profound coordinated negative-feedback program consistent with a reduced immune recognition and defense pathway signatures, and offers deeper insights into how chronic inflammation impairs host defenses against viral and tumor cells.
E. Mazzio, A. Barnes, R. Badisa et al.· Frontiers in Immunology· 0 citations
Innate immunity provides a critical first line of defense against pathogens and homeostatic perturbations. Pattern recognition receptors detect these disruptions and initiate immune responses through multi-protein complex formation to drive inflammatory signaling and cell death pathways. Key cytosolic complexes formed...
Saurabh Upadhyay, R. Nagampalli, S. Resende et al.· Cell Research· 1 citation
The development of tuberculosis (TB) is dictated by a complicated interplay between antimicrobial defense and host‐mediated immunopathology. Neutrophils are known to exhibit striking functional plasticity with phenotypes associated with both bacterial containment and tissue damage. However, the mechanisms that connect...
K. Hamdan, J. Rizaev, Dhara N. Patel et al.· Cell Biology International· 0 citations
Abstract Background and Aims Type I interferons (IFN-Is) are central regulators of intestinal epithelial homeostasis, yet their role in driving epithelial dysfunction and therapeutic non-response in Crohn’s disease (CD) remains poorly defined. Here, we investigated epithelial tumor necrosis factor (TNF)–IFN-I crosstalk...
Safina Gadeock, Mikayla R. King, D. Polk et al.· Journal of Crohn's & Colitis· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.